Welcome to our dedicated page for Psyence Biomedical Ltd. SEC filings (Ticker: PBM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Psyence Biomedical Ltd. (PBM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on the Nasdaq Capital Market. Psyence BioMed files under Form 20-F and furnishes interim and event-driven information on Form 6-K, as reflected in the available filings.
Through these filings, investors can review unaudited interim condensed consolidated financial statements and accompanying Management’s Discussion and Analysis for specified periods, as referenced in a Form 6-K describing financial statements for the three and six months ended September 30 in certain years. Exhibits to Form 6-K reports may also include press releases, equity incentive plan documents, and details of material agreements.
Some PBM filings describe corporate and governance developments, such as changes in executive roles, appointments to the Board of Directors, and amendments to capital arrangements. For example, a Form 6-K outlines the appointment of the company’s Chief Financial Officer to the Board and the entry into an amendment to a Common Stock Purchase Agreement with an investor, providing context on the company’s access to capital.
Other Form 6-K submissions incorporate press releases on topics such as clinical trial progress, strategic investments in PsyLabs, and share-related actions. These filings may be incorporated by reference into the company’s shelf registration statements on Form F-3, as indicated in the text of certain reports.
On Stock Titan, PBM filings are updated as new documents are posted to the SEC’s EDGAR system. AI-powered summaries can help explain key elements of lengthy filings, highlight changes in capital structure, and clarify the implications of agreements or governance updates. Users can quickly scan for items such as interim financial results, capital management disclosures, and material contracts, and can also monitor how press releases referenced in filings align with the company’s broader clinical and strategic narrative.
Psyence Biomedical Ltd. filed a prospectus supplement to its F-1 prospectus to update it with a newly furnished Form 6-K. The 6-K reports two items: the Board appointed Chief Financial Officer Warwick Corden-Lloyd as a director effective October 30, 2025, and the Company entered Amendment No. 2 to its Common Stock Purchase Agreement with White Lion Capital LLC on November 4, 2025.
The amendment increases potential aggregate drawdown capacity, extends the commitment period, introduces a VWAP-based purchase mechanic with per-notice caps tied to trading volume (subject to waiver), clarifies closing timing and funds flow, updates short sales provisions, and makes conforming changes. The filing also furnishes press releases dated November 6, 2025 on dosing progress in a Phase IIb study and November 3, 2025 noting a USD $3,500,000 follow-on investment by PsyLabs. Except for the press release materials, the 6-K is incorporated by reference into the Company’s F-3 registration statement.
Psyence Biomedical Ltd. reported two updates. The Board appointed Chief Financial Officer Warwick Corden‑Lloyd as a director effective October 30, 2025, to serve until the next annual general meeting or until a successor is elected. He remains an employee in his CFO role and does not receive separate Board compensation.
The Company also entered Amendment No. 2 to its Common Stock Purchase Agreement with White Lion Capital LLC on November 4, 2025. The amendment increases potential aggregate drawdown capacity, extends the commitment period, adds a VWAP-based purchase mechanic after certain funding thresholds are met (with per‑notice caps tied to trading volume, subject to waiver), clarifies timing of closings and funds flow, updates short‑sale provisions, and makes conforming changes. The Company furnished press releases dated November 6, 2025 and November 3, 2025 as exhibits.
Psyence Biomedical Ltd. registered 50,000,000 Common Shares for potential resale by White Lion Capital under a previously established equity line. The company is not selling securities in this prospectus; White Lion, deemed an underwriter, may resell shares from time to time as described in the Plan of Distribution.
Psyence may receive gross proceeds only when it sells shares to White Lion under the purchase agreement. To date, Psyence has sold an aggregate of $14,026,983 and may sell up to another $10,973,107 of Common Shares under the $25,000,000 facility. The prospectus notes these resales represent vastly more than current outstanding shares and could pressure the share price. Common Shares outstanding were 1,872,051 as of September 30, 2025. PBM and PBMWW trade on Nasdaq; on October 31, 2025, PBM closed at $3.16 and PBMWW at $0.029.
Psyence Biomedical Ltd. announced a leadership reorganization. Dr. Neil Maresky has transitioned from his positions as Chief Executive Officer and Director to become the company’s Global Head, Clinical Development, where he will lead global clinical programs, including its Phase 2b clinical trial in Australia. In connection with this change, the company’s Chairman, Jody Aufrichtig, has assumed the role of Chief Executive Officer and will oversee Nasdaq-related and corporate operations. The board seat vacated by Dr. Maresky will be filled by a vote of a quorum of directors or at the next annual general meeting of shareholders, in line with applicable law and the company’s governing documents.
Psyence Biomedical (Nasdaq: PBM) filed its FY-2025 Form 20-F covering the year ended March 31 2025.
Key disclosures include:
- 568,021 common shares outstanding at year-end
- Securities trade as PBM (shares) and PBMWW (warrants) on Nasdaq
- Reports under IFRS; classified as a non-accelerated filer and emerging growth company
- Not a well-known seasoned issuer; no SOX 404(b) auditor attestation
- Company has no products yet approved for commercial sale and depends on successful clinical trials and regulatory clearance
- Forward-looking statements flag risks around Nasdaq listing stability, share price volatility, talent retention, supply chain, IP licensing and macro conditions
The filing provides full audited financials, risk factors and corporate-governance disclosures but does not announce new financings, M&A or product approvals.